Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter Licenses Platelet System To Haemonetics, Anticipates 2003 Approval

This article was originally published in The Gray Sheet

Executive Summary

Baxter expects FDA approval by mid-2003 for its Intercept platelet blood screening system, licensed to Haemonetics in a deal announced Dec. 10

You may also be interested in...



Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data

Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete

Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data

Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete

Vitex Takes On Baxter: Will Parallel Study Favor Swift Inactine Approval?

A parallel arm design for Vitex' Phase III pivotal trial testing the Inactine red blood cell pathogen inactivation system in chronic anemia patients positions Vitex to be the first to market in the U.S., according to the firm

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel